Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07229716 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects

StatusCompleted
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial completed Primary and study completion dates changed from estimate of May 2026 to Jun 18, 2026 · Eligibility criteria expanded, about 19 words · Site details revised Show 3 more changesShow less
    • Primary and study completion dates changed from estimate of May 2026 to Jun 18, 2026
    • Eligibility criteria expanded, about 19 words
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Nov 2025 to Apr 4, 2026 · Primary and study completion dates: Apr 2026 to May 2026 · Site details revisedv2 Show 3 more changesShow less
    • Start date changed from estimate of Nov 2025 to Apr 4, 2026
    • Primary and study completion dates: Apr 2026 to May 2026
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to evaluate the interaction of oral HRS-9813 capsules with pirfenidone and nintedanib on the pharmacokinetics of healthy subjects.
Trial Details
NCT Number NCT07229716
Lead Sponsor Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions Pulmonary Fibrosis
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov